Observational studyInternational journal of clinical oncology2026
Survival and prognostic factors in vaginal cancer: an analysis of 2016-2020 nationwide data.
Observational study in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaginal cancer is a rare gynecological malignant disease. In Japan, the proportion of vaginal cancer cases is estimated to increase as the population ages. The purpose of this study is to evaluate the age-specific incidence, treatment options, and prognosis of vaginal cancer in Japan.
methodsThis retrospective observational study used the Japan Society of Obstetrics and Gynecology tumor registry database. Patient characteristics included age, year diagnosed with vaginal cancer (2016-2020), and cancer stages, histological types, and treatment methods. The 2016 and 2017 dataset included follow-up time, survival status, and cause of death.
resultsA total of 746 patients were diagnosed with vaginal cancer from 2016 to 2020. The median age of the patients was 72 years. Radiotherapy was most chosen as the primary treatment option for all ages and stages. Surgery was selected mostly in stage I and II (n = 118, 22.2% of these stage patients). Five-year overall survival for stages I, II, III, and IV was 87.6%, 55.6%, 59.9%, and 15.3%, respectively. Multivariate analysis showed that 3 year OS was significantly better for patients who underwent surgery than those who received chemotherapy (HR 3.11, P = 0.00389) and those who received radiation therapy (HR 2.89, P = 0.0241), but not compared with concurrent chemoradiotherapy (HR 1.21, P = 0.7091). Histological type did not significantly affect prognosis. For stages I and II, surgery resulted in a better prognosis than radiation (P = 0.03).
conclusionsRadiation therapy is the primary treatment for vaginal cancer; however, surgery may be an effective option in early-stage vaginal cancer when cases are appropriately selected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.